← All trials
NCT04792333
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 17, 2019
- Primary completion
- Jul 10, 2020
- Completion date
- Jul 10, 2020
- First posted
- Mar 10, 2021
- Last posted
- Mar 10, 2021
- Enrollment
- 28
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Quantum Genomics SALead sponsor
- EurofinsOverall official - principal investigator
- EurofinsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.